NSE / BSEHealthcare
β‚Ή572.50-3.70-0.64%
P/E24.6Mkt Capβ‚Ή8.66 K CrEV/EBITDA34.4

Blue Jet Healthcare Limited

P/E24.6Mkt Capβ‚Ή8.66 K CrEV/EBITDA34.4
Company Profile

Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
β€”
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 27.84% over 1Y
Monthly Returns

Historically, May has averaged the highest return (+8.2%); Aug the lowest (-7.1%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-21.2%Negative MonthJan 2026: -21.23%-3.0%Negative MonthFeb 2026: -2.98%-19.2%Negative MonthMar 2026: -19.20%+35.5%Positive MonthApr 2026: +35.54%-0.7%Neutral MonthMay 2026: -0.68%+19.1%Positive MonthJun 2026: +19.06%+9.2%*Positive MonthJul 2026: +9.15%β€”β€”β€”β€”β€”
2025+32.9%Positive MonthJan 2025: +32.91%+0.6%Neutral MonthFeb 2025: +0.61%+16.7%Positive MonthMar 2025: +16.71%-19.2%Negative MonthApr 2025: -19.19%+27.1%Positive MonthMay 2025: +27.06%-2.9%Negative MonthJun 2025: -2.85%-8.3%Negative MonthJul 2025: -8.26%-17.2%Negative MonthAug 2025: -17.20%-5.5%Negative MonthSep 2025: -5.54%+4.1%Positive MonthOct 2025: +4.12%-12.0%Negative MonthNov 2025: -12.00%-8.2%Negative MonthDec 2025: -8.24%
2024-3.8%Negative MonthJan 2024: -3.80%-3.1%Negative MonthFeb 2024: -3.06%+11.4%Positive MonthMar 2024: +11.44%+1.7%Neutral MonthApr 2024: +1.71%-1.7%Neutral MonthMay 2024: -1.72%+5.7%Positive MonthJun 2024: +5.66%+17.4%Positive MonthJul 2024: +17.44%+3.1%Positive MonthAug 2024: +3.10%+3.8%Positive MonthSep 2024: +3.81%-6.9%Negative MonthOct 2024: -6.92%+9.9%Positive MonthNov 2024: +9.86%+8.7%Positive MonthDec 2024: +8.70%
2023β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”+2.4%Positive MonthDec 2023: +2.36%
AvgΒ±SD+2.6%Β±22.6%-1.8%Β±1.7%+3.0%Β±15.8%+6.0%Β±22.5%+8.2%Β±13.3%+7.3%Β±9.0%+6.1%Β±10.7%-7.1%Β±10.2%-0.9%Β±4.7%-1.4%Β±5.5%-1.1%Β±10.9%+0.9%Β±7.0%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 4 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.080x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή1.03 K Crβ–² 44.7%
EBITDA Growthβ€”
Net Profitβ‚Ή305.00 Crβ–² 86.0%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 66.7%
Revenue CAGR 5Y5.8%
EBITDA CAGR 5Y2.5%
Net Profit CAGR 5Y2.5%
NP Growth 1Y86.0%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή1.03 K Crβ€”β‚Ή305.00 Crβ€”β€”26.9%44.7%86.0%
Mar 2024β‚Ή712.00 Crβ€”β‚Ή164.00 Crβ€”β€”19.4%-1.2%2.5%
Mar 2023β‚Ή721.00 Crβ€”β‚Ή160.00 Crβ€”β€”23.5%5.6%-12.1%
Mar 2022β‚Ή683.00 Crβ€”β‚Ή182.00 Crβ€”β€”34.9%36.9%28.2%
Mar 2021β‚Ή499.00 Crβ€”β‚Ή142.00 Crβ€”β€”41.8%-7.2%-2.1%
Mar 2020β‚Ή538.00 Crβ€”β‚Ή145.00 Crβ€”β€”73.0%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales5384996837217121,0301,179
Total Expenses325292434502481652739
EBIT / Operating Profit214207249219231378440
OPM %40%41%36%30%32%37%37%
Other Income691924184658
Finance Costs7531005
Depreciation & Amortisation18202225281821
Profit Before Tax194190243217220406471
Tax %25%26%25%26%26%25%-
Net Profit / PAT145142182160164305352
EPS (β‚Ή)24,118.331,428.7710.479.239.4417.5920.33
Dividend Payout %0%0%0%0%11%7%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Blue Jet Healthcare Limitedthis co.β‚Ή8.66 K Crβ‚Ή1.03 K Cr24.606.8934.3944.7%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Blue Jet Healthcare Limited and the metrics that matter.

Browse the full Equiscale Academy